Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPPL2A | Q8TCT8 | 2/20 | 0.47 |
| ▸ | RORC | P51449 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MLNR | O43193 | 1/20 | 0.41 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CTSD | P07339 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28778215 | 1.00 | SPPL2A (0.47) | SPPL2ARORCALDH1A1KMT2AMAPK1 | |
| SCHEMBL1813344 | 0.89 | SPPL2A (0.48) | SPPL2ARORCALDH1A1KMT2AMAPK1 | |
| SCHEMBL1057299 | 0.88 | SPPL2A (0.52) | SPPL2ARORCTAS2R14MLNRABCB11 | |
| SCHEMBL1058927 | 0.88 | SPPL2A (0.47) | SPPL2ARORCALDH1A1TAS2R14MLNR | |
| SCHEMBL2582086 | 0.88 | SPPL2A (0.48) | SPPL2ARORCALDH1A1KMT2AMAPK1 | |
| SCHEMBL6872886 | 0.87 | SPPL2A (0.49) | SPPL2ARORCALDH1A1KMT2AMAPK1 | |
| SCHEMBL1058694 | 0.87 | SPPL2A (0.55) | SPPL2AALDH1A1LMNA | |
| SCHEMBL1058578 | 0.87 | SPPL2A (0.48) | SPPL2ARORCTAS2R14MLNRABCB11 | |
| SCHEMBL1053311 | 0.86 | SPPL2A (0.48) | SPPL2ARORCTAS2R14MLNRABCB11 | |
| SCHEMBL1059009 | 0.86 | PTGES (0.49) | TAS2R14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114685324-A | anti-HIV drug intermediate crystal form and preparation method thereof | 重庆博腾制药科技股份有限公司 | 2022-07-01 | — | — | CN | claimed |
| CN-114685327-A | anti-HIV drug intermediate crystal form and preparation method thereof | 重庆博腾制药科技股份有限公司 | 2022-07-01 | — | — | CN | claimed |
| CN-114685326-A | Novel crystal form of anti-HIV drug intermediate and preparation method thereof | 重庆博腾制药科技股份有限公司 | 2022-07-01 | — | — | CN | claimed |
| CN-114685327-A | anti-HIV drug intermediate crystal form and preparation method thereof | 重庆博腾制药科技股份有限公司 | 2022-07-01 | — | — | CN | disclosed |
| CN-114685326-A | Novel crystal form of anti-HIV drug intermediate and preparation method thereof | 重庆博腾制药科技股份有限公司 | 2022-07-01 | — | — | CN | disclosed |
| CN-114685324-A | anti-HIV drug intermediate crystal form and preparation method thereof | 重庆博腾制药科技股份有限公司 | 2022-07-01 | — | — | CN | disclosed |
| US-8193227-B2 | HIV protease inhibiting compounds | ABBOTT LABORATORIES (US) | 2012-06-05 | — | — | US | disclosed |
| US-20120041019-A1 | PROTEASE INHIBITORS | AMPLYX PHARMACEUTICALS, INC. | 2012-02-16 | — | — | US | disclosed |
| WO-2011061590-A1 | NOVEL CARBOXAMIDE DERIVATIVES AS HIV INHIBITORS | HETERO RESEARCH FOUNDATION (IN) | 2011-05-26 | — | — | WO | disclosed |
| US-20110003827-A1 | HIV protease inhibiting compounds | ABBVIE INC. | 2011-01-06 | — | — | US | disclosed |
| US-20050131042-A1 | HIV protease inhibiting compounds | ABBOTT LABORATORIES | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003827-A1 | HIV protease inhibiting compounds | SERPINB1, HPN, DNPEP | SPPL2A 1106/4885RORC 3674/4885ALDH1A1 2920/4885 |
| US-20120041019-A1 | PROTEASE INHIBITORS | SERPINB1, PREP, DNPEP | SPPL2A 342/4885RORC 3722/4885ALDH1A1 2740/4885 |
| US-20050131042-A1 | HIV protease inhibiting compounds | SERPINB1, HPN, DNPEP | SPPL2A 1106/4885RORC 3674/4885ALDH1A1 2920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.